FT Pharmaceutical and Biotechnology Conference 2010

The global life sciences industry faces an unprecedented array of challenges. Adding to the already heady mix of patent expirations and falling R&D productivity comes the challenge of new healthcare reforms in the US, and the advent of evidence based medicine as a global phenomenon with the potential to transform the fortunes and business models of the industry. Faced with these new realities, how can life science companies prepare?

Chaired by Andrew Jack, Pharmaceuticals Correspondent of the Financial Times, the FT Global Pharmaceutical and Biotechnology Conference, now in its 27th successful year, brings together leading industry executives, government decision makers, investors, analysts and other specialist providers to discuss the latest industry developments, and provide insights that will help you identify, anticipate and meet tomorrow's challenges head on .